×

SteadyMed to Participate in Upcoming Investor Conferences

SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer and David Nassif, Chief Financial Officer, will provide an overview of the company's business including its lead development program and additional pipeline opportunities at the following investor conferences respectively:

  • Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, September 9, 2015 at 12:05 p.m. EDT (9:05 a.m. PDT) in New York.
  • 10th Annual Well Fargo Healthcare Conference on Thursday, September 10, 2015 at 10:55 a.m. EDT (7:55 a.m. PDT) in Boston.

A live audio webcast and archive of each presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. In June 2015, SteadyMed signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.

CONTACT: Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com Robert H. Uhl Managing Director Westwicke Partners 858-356-5932 robert.uhl@westwicke.com

Source: SteadyMed Therapeutics